Brian S. Kim, MD
img_Brian S. Kim
PROFESSOR | Dermatology
Are you a patient?
Research Topics
Multi-Disciplinary Training Area
Neuroscience [NEU]

MD, University of Washington School of Medicine

Internship, Internal Medicine, University of Washington School of Medicine

Residency, Dermatology, Hospital of the University of Pennsylvania


American Board of Dermatology

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Kim during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • GlaxoSmithKline
  • Pfizer Inc.
  • Granular Therapeutics
  • Incyte Corporation
  • Eli Lilly and Company
  • Abrax Japan
  • Guidepoint Global
  • Blueprint Medicines
  • Cara Therapeutics
  • Trevi Therapeutics
  • Argenx
  • Shaperon
  • Almirall, S.A.
  • Galderma S.A.
  • Amagma
  • Bellus Health
  • Bristol-Myers Squibb
  • Escient Pharmaceuticals
  • LEO Pharma Inc.
  • AbbVie Inc.
  • Recens Medical
  • Novartis
  • Regeneron Pharmaceuticals
  • Granular Therpaeutics
  • Janssen Pharmaceuticals, Inc.
  • Genzyme Corporation
  • LEO Pharma A/S

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Locus Biosciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.